Skip to main content
Premium Trial:

Request an Annual Quote

Harvard Bioscience Shares Sink on Weak Genomic Solutions Results

This article has been updated to include share prices and details.

NEW YORK, Oct. 29 (GenomeWeb News) - Shares in Harvard Bioscience were down more that 8 percent to $3.74 in late-afternoon trade today after the company said poor performance from its Genomic Solutions unit acted as ballast on third-quarter revenue.

The company also lowered by $2.2 million its revenue outlook for the fourth quarter. However, Harvard said that increased product sales in its core product lines helped it report a modest gain in total revenue.

Receipts for the quarter ended Sept. 30 totaled $23.2 million, up from $21.1 million during the same period a year ago. HBIO said it is seeing strong growth in some its core product lines, such as animal physiology products, cell-biology products, and plate readers.

"However, the revenue trend at Genomic Solutions continues to track lower than we expected," CEO Chane Graziano said in a statement. Revenue for that business segment fell 29 percent year over year, and accounted for around 25 percent of total revenue for Harvard Bio.

 

R&D costs increased to $1.9 million in the quarter from $1.6 million during the year-ago quarter.

 

Harvard Bioscience had a net income of $957,000, or $.03 per share, compared to $986,000, or $.03 per share, during the same quarter last year.

 

As of Sept. 30, Harvard Bioscience had cash and cash equivalents of $11.6 million.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.